SynthesisLipids in health and disease2020
Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.
Synthesis in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 7 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Pooled it
- Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies.Frontiers in oncology · 2024Pooled it
- Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.Frontiers in oncology · 2024Pooled it
- 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.European urology · 2023Pooled it
- Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis.Lipids in health and disease · 2022Pooled it
- Risk factors for gastric cancer: A comprehensive analysis of observational studies.Frontiers in public health · 2022Pooled it
- The impact of hepatic steatosis on outcomes of colorectal cancer patients with liver metastases: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis.Gut and liver · 2026Article
- FGF1 ameliorates hepatic steatosis through acute activation of the unfolded protein response and VLDL production.JHEP reports : innovation in hepatology · 2026Article
- Development of automated machine learning models in predicting colorectal adenoma in metabolic-associated steatotic liver disease.Frontiers in medicine · 2026Article
- Splenic Steatopathy: A Clinical and Experimental Framework for Lipid-Associated Splenic Pathology.Clinical and experimental gastroenterology · 2026Review
- An Interpretable Machine Learning Model Based on Inflammatory-Nutritional Biomarkers for Predicting Metachronous Liver Metastases After Colorectal Cancer Surgery.Biomedicines · 2025Article
- Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review.Metabolites · 2025Review
- [Metabolic-associated fatty liver disease (MAFLD): a multisystemic disease beyond the liver].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease.Biomedicines · 2025Article
- Article
- Unveiling the cancer risk nexus of the steatotic liver.Trends in endocrinology and metabolism: TEM · 2024Review
- Association between non-alcoholic fatty liver disease and the risk of pulmonary nodules in patients with intestinal polyps.Journal of thoracic disease · 2024Article
- Development and validation of a clinical prediction model for the risk of distal metastasis in intrahepatic cholangiocarcinoma: a real-world study.BMC gastroenterology · 2024Article
- Utility of Alpha-Fetoprotein and Ultrasound in the Diagnosis and Prognosis of Patients with Hepatocellular Liver Cancer.Journal of multidisciplinary healthcare · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNAFLD is tightly associated with various diseases such as diabetes, cardiovascular disease, kidney disease, and cancer. Previous studies had investigated the association between NAFLD and various extrahepatic cancers, but the available data to date is not conclusive. The aim of this study was to investigate the association between NAFLD and various extrahepatic cancers comprehensively.
methodsSearches were conducted of various electronic databases (PubMed, EMBASE, Medline, and the Cochrane Library) to identify observational studies published between 1996 and January 2020 which investigated the association between NAFLD and extrahepatic cancers. The pooled OR/HR/IRR of the association between NAFLD and various extrahepatic cancers were analyzed.
resultsA total of 26 studies were included to investigate the association between NAFLD and various extrahepatic cancers. As the results shown, the pooled OR values of the risk of colorectal cancer and adenomas in patients with NAFLD were 1.72 (95%CI: 1.40-2.11) and 1.37 (95%CI: 1.29-1.46), respectively. The pooled OR values of the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in patients with NAFLD were 2.46 (95%CI: 1.77-3.44) and 2.24 (95%CI: 1.58-3.17), respectively. The pooled OR value of the risk of breast cancer in patients with NAFLD was 1.69 (95%CI: 1.44-1.99). In addition, NAFLD was also tightly associatied with the risk of gastric cancer, pancreatic cancer, prostate cancer, and esophageal cancer.
conclusionsNAFLD could significantly increase the development risk of colorectal adenomas and cancer, intrahepatic and extrahepatic cholangiocarcinoma, breast, gastric, pancreatic, prostate, and esophageal cancer. NAFLD could be considered as one of the influencing factors during the clinical diagnosis and treatment for the extrahepatic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.